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Background: Osteosarcoma is the most frequent primary malignant bone tumor, notorious for its lung metastasis.
Shikonin, an effective constituent extracted from Chinese medicinal herb, was demonstrated to induce necroptosis
in some cancers.
Methods: MTT assay was performed to detect cell survival rate in vitro. Flow cytometry was used to analyze cell
cycle and cell death. Western blot was performed to determine the expression levels of RIP1, RIP3, caspase-3,
caspase-6 and PARP. The tibial primary and lung metastatic osteosarcoma models were used to evaluate the
anti-tumor effect of shikonin in vivo.
Results: The cell survival rate was decreased in a dose and time dependent manner when treated with shikonin.
No major change in cell cycle was observed after shikonin treatment. The cell death induced by shikonin could be
mostly rescued by specific necroptosis inhibitor necrostatin-1, but not by general caspase inhibitor Z-VAD-FMK. The
number of necrotic cells caused by shikonin was decreased after being pretreated with Nec-1 detected by flow
cytometry in K7 cells. After 8-hour treatment of shikonin, the expression levels of RIP1 and RIP3 were increased
while caspase-3, caspase-6 and PARP were not activated in K7 and U2OS cells determined by Western blot. Size of
primary tumor and lung metastasis in shikonin treated group were significantly reduced. The protein levels of RIP1
and RIP3 in primary tumor tissues were increased by shikonin. The overall survival of lung metastatic models was
longer compared with control group (p < 0.001).
Conclusions: Shikonin had prompt but profound anti-tumor effect on both primary and metastatic osteosarcoma,
probably by inducing RIP1 and RIP3 dependent necroptosis. Shikonin would be a potential anti-tumor agent on the
treatment of primary and metastatic osteosarcoma.
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Osteosarcoma is the most common primary malignant
bone tumor accounting for approximately 60% of all bone
sarcoma [1,2]. With the advance of chemotherapy,
although the long-term cure rate after surgery for non-
metastatic osteosarcoma has risen from 25% to 60% [3],
the survival rate for osteosarcoma is still rather low. Most
osteosarcomas are high grade with part of them were
accompanied by lung metastasis [4]. Metastatic disease is
usually not sensitive to conventional chemotherapy with* Correspondence: hua_yingqi@163.com; zhdcai@gmail.com
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reproduction in any medium, provided the orlong-term survival rate approximately 20% [5]. Therefore,
the development of chemotherapy for osteosarcoma is
urgently needed.
For a long time, apoptosis was regarded as the sole
form of programmed cell death, while necrosis was con-
sidered as an unregulated and uncontrollable process. In
2004, Zong, WX, et al. found a regulated form of
necrotic cell death during the damage of DNA [6], which
was named as “necroptosis” later and suggested that
necrosis might not be absolutely unregulated. In 2005,
Degterev, A, et al. found that Nec-1 (necrostatin-1) was
a specific inhibitor of necroptosis [7]. The idea of
“necroptosis” was demonstrated by a series of subse-
quent studies in which increasing signal moleculesThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as receptor-interacting protein 1 [8] (RIP1, RIPK1) and
receptor-interacting protein 3 [9,10] (RIP3, RIPK3) or in-
hibitors such as necrostatin-1 (Nec-1), were discovered.
Since necroptosis is a pathway separate from apoptosis,
all the barriers set up in cancer cells to avoid apoptosis
are no longer problems for necroptosis [11].
Shikonin, an effective constituent, purified from
Lithospermum erythrorhixon, a Chinese medicinal herb,
was widely used in anti-inflammatory process [12,13]. Shiko-
nin was thought to have anti-tumor effect by inducing apop-
tosis until people found that shikonin could circumvent
cancer drug resistance by inducing necroptosis in 2007
[11,14]. Interestingly shikonin also exert two death modes of
apoptosis and necroptosis in KL-60 cells depending on its
concentrations [15]. Moreover, shikonin was demonstrated
to mediated necrotic cell death via a RIP1-RIP3 complex
similar to TNFα-directed necrotic cell death, and this prone-
crotic complex was blocked by a reactive oxygen species
(ROS) scavenger or Nec-1 concomitantly with protection
against cell death [16]. In 2011, the first molecular target of
shikonin was reported in which shikonin played a role in
the anti-tumor effect by inhibiting pyruvate kinase-M2
(PKM2). PKM2 is universally over expressed in cancer cells
and dictated to the last rate-limiting step of glycolysis vital
for cancer cell proliferation [17]. Recently, shikonin was also
found to be a cytotoxic DNA-binding agent [18]. Further-
more, shikonin and its analogs were demonstrated hardly to
inducer cancer drug resistance [19]. The effect of shikonin
on bone sarcomas is still unclear. In this study, we tested
whether shikonin had anti-tumor effect on osteosarcoma
and explored the underlying mechanism.
Methods
Cell Lines and culture
Murine osteosarcoma cell lines K7, K12 and K7M3 cell
lines were from Dr. Kleinerman’s lab in MD Anderson
Cancer Center which were originally established by
Khanna [20]. Human osteosarcoma cell lines U2OS and
143B cell lines were obtained from American Type Cul-
ture Collection (ATCC). All cells were cultured in high
glucose Dulbecco’s Modified Eagle’s Medium (DMEM-h;
Thermo, America) supplemented with 10% fetal bovine
serum (Thermo, America), 100 U/ml penicillin and
100 μg/ml streptomycin (Thermo, America) in a humidi-
fied incubator at 37°C in 5% CO2.
Drugs and antibodies
Purified shikonin (>98%) was purchased from Shanghai
Tauto Biotech Co., Ltd. Stock solution at 50 mM was
made in dimethyl sulfoxide (DMSO; Sigma, America)
and stored in the dark at −20°C. The final shikoninconcentrations used for different experiments were pre-
pared by diluting the stock solution with DMEM-h. The
antibodies used for Western blot were as follows: rabbit
anti-Actin (Santa Cruz, CA, USA), anti-caspase-3 (Cell
Signaling Technology Inc., Danvers, MA), anti-caspase-6
(Cell Signaling Technology Inc., Danvers, MA), anti-PARP
(Cell Signaling Technology Inc., Danvers, MA) and mouse
anti-RIP1 (BD, CA, USA), anti-RIP3 (Abcam, USA).
MTT assay
Cells were seeded into 96-well plates (cultured overnight
for adherent cells) and treated with shikonin at a series
of concentrations (0, 1, 3, 5, 7.5, 10, 12.5, 15 μΜ) for
8 hours or treated with shikonin (3 μΜ) for 8, 16 or
24 hours. Cells incubated with DMEM-h were regarded
as control group. After 8, 16 or 24-hour incubation,
20 μl MTT (5 mg/ml, Sigma, America) was added into
each well for another 4-hour incubation. After that, the
supernatant was removed and 150 μl DMSO was added
into each well in order to solubilize the blue-purple crys-
tals of formazan. The absorbance was then measured
using a model ELX800 Micro Plate Reader (Bio-Tec In-
struments, Inc.) at 490 nm. The survival rate was calcu-
lated according to the following formula: Survival rate =
Absorbance of treatment / Absorbance of control × 100%.
In the inhibition experiment, K7, K12, K7M3 and
U2OS cells were treated with shikonin (3 μΜ) while
143B cells were treated with shikonin (6 μΜ) in the ab-
sence or presence of necrostatin-1 (Nec-1; Sigma, Amer-
ica) or Z-VAD-FMK (Sigma, America) for 8 hours. The
cell survival rate was measured by MTT assay. When
added MTT, the supernate in the well with Nec-1 was
discarded and added DMEM-h again.
Flow cytometry analysis
Osteosarcoma cells (K7, K12, K7M3, U2OS and 143B)
were plated in 6-well plates and synchronized with
DMEM-h containing 10% fetal bovine serum. After 8-
hour incubation, control cells (incubated with DMEM-
h) and shikonin-treated cells (143B cells were treated
with 6 μΜ shikonin while other cells were treated with 3
μΜ shikonin) in the presence or absence of Nec-1 (50
μΜ) were collected, washed twice in cold PBS. The cells
used in cell cycle were mixed in 300 μl of 1× binding
buffer, and incubated at room temperature for 15 min
with propidium dide (PI, Sigma, America), NP-40, and
RnaseA (BD Biosciences) while the cells used in cell
death were mixed in 100 μl of 1× binding buffer, and in-
cubated at room temperature for 15 min with an
annexin-V/PI (BD Biosciences) double staining solution.
Stained cells were analyzed by flow cytometry. The per-
centage of cells in the different stages and the
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Fit LT software (Verity Software House).
Western blot assay
K7, U2OS and 143B cells were treated with different
concentrations of shikonin for 8 hours. Cells were
washed twice with PBS solution, lysed with RIPA Lysis
Buffer (Beyotime Institune of Biotechnology, Shanghai,
China) and protease inhibitor (Thermo scientific).
Tumor tissues were retrieved from −80°C storage and
immersed rapidly in liquid nitrogen. The resulting pow-
der was lysed with RIPA Lysis Buffer and protease in-
hibitor. Protein concentrations were determined with
Pierce BCA Protein Assay Kit (Thermo Scientific).
Equivalent amounts of total protein (50 μg) were boiled
and electrophoretically seperated on a 10% polyacryl-
amide gel at 80 volts. The proteins were transferred to a
nitrocellulose filter membrane. Membranes were
blocked for 60 min with 5% milk solutions prepared in
PBS, incubated overnight at 4°C with 1:1000 dilutions of
the primary antibodies (RIP1, RIP3, PARP, caspase-3,
caspase-6 and Actin), washed three times for 10 min
each time with Tween 20 (1:1000 dilution)-PBS, incu-
bated for 1 hour with the appropriate peroxidase-
conjugated secondary antibody (1:1000 dilution). Mem-
branes were washed with Tween 20-PBS three times for
10 min each and were developed using the Odyssey two-
color infraed laser imaging system. The signal generated
by Action was used as an internal control.
Animal experiments
Animal experiments were performed on 4-week-old fe-
male mice (BALB/C). Mice were housed in a standard
animal laboratory with free access to water and food.
They were kept under constant environmental condi-
tions with a 12-hour light–dark cycle. All operations
were performed under aseptic conditions. All the
animal-related procedures were approved by the Animal
Care and Use Committee of The Tenth People's Hospital
of Shanghai. This study was also approved by the Sci-
ence and Technology Commission of Shanghai Munici-
pality (ID: SYXK 2007–0006) with the permit number
2011-RES1.
Mice tibial tumor models and treatment regimen
Balb/c mice (4 weeks of age) were purchased from
Shanghai Slac Laboratory Animal Co., Ltd. K7 cells were
digested and washed by cold PBS for three times, sus-
pended in cold PBS. The final concentration of K7 cells
was 1 × 108/ml. The cell suspension (10 μl) was injected
into medullary cavity of tibia. Mice were divided into
two groups, shikonin group and control group (each had
10 mice). Three weeks later, when the tumors in the
tibia were macroscopic, shikonin group was injectedwith shikonin (2.0 mg/kg, diluted with 5% DMSO) while
control group was injected with 5% DMSO. Both groups
were injected intraperitoneally every other day for seven
times in all. The mice were euthanized two days after
the last injection. The primary tumor size and lung me-
tastasis were observed. Posterior limb with tumors and
lungs were weighted. Necrotic degree of primary tumors
and lung metastasis was detected by HE stain. The ex-
pression levels of RIP1 and RIP3 in primary tumor tis-
sues were determined by Western blot.
Mice lung metastatic models and treatment regimen
Balb/c mice (4 weeks of age) were purchased from
Shanghai Slac Laboratory Animal Co., Ltd. K7 cells were
digested and washed by cold PBS for three times, sus-
pended in cold PBS. The final concentration of K7 cells
was 5 × 106/ml. The cell suspension (100 μl) was injected
into the mice from caudal vein. Two weeks later, mice
were divided into two groups (each had 10 mice), experi-
mental group was injected with shikonin (2.0 mg/kg, di-
luted with 5% DMSO), control group was injected with
5% DMSO. Both groups were injected intraperitoneally
every other day.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5 (La Jolla, CA, USA). All measurement data were
expressed as mean ± standard deviation (SD), and com-
pared between two groups using Student’s t test. P < 0.05
was considered statistically significant.
Results
Shikonin had prompt killing effect on osteosarcoma cells
We firstly evaluated the cytotoxity of shikonin on osteo-
sarcoma cells in vitro. Cells were treated with shikonin
in different concentrations for 8 hours. The IC50 of K7,
K12, K7M3, U2OS, 143B was 2.87, 2.72, 3.02, 3.18,
6.45 μΜ respectively at 8-hour treatment of shikonin
(Figure 1A). The cell survival rate decreased time-
dependently with the treatment of shikonin (3 μΜ) for
8, 16 and 24 hours (Figure 1B). The decrease of cell via-
bility happened in a quick fashion within the first 8-hour
in osteosarcoma cells. Conventional chemotherapy agent
such as cisplatin and doxorubicin showed almost no cell
killing effect at 8-hour theatment in IC50 dosage (data
not shown).
We then tested the cell cycle change after shikonin
treatment of osteosarcoma cells (K7, K12, K7M3, U2OS,
143B). There was no significant change in cell cycle after
being treated with shikonin for 8 hours in the absence
or presence of Nec-1 detected by flow cytometry
(Figure 1C). All these data suggested that shikonin had
very prompt but profound cell killing effect on osteosar-
coma cells.
Figure 1 (See legend on next page.)
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Figure 1 The prompt anti-tumor effect of shikonin on osteosarcoma cells. (A) Osteosarcoma cells (K7, K12, K7M3, U2OS, 143B) were
treated with shikonin in different concentrations (0, 1, 3, 5, 7.5, 10, 12.5, 15 μΜ) for 8 hours. The cell survival rate was measured by MTT assay.
(B) Osteosarcoma cells (K7, K12, K7M3, U2OS, 143B) were treated with shikonin (3 μΜ) for 8, 16 or 24 hours. The cell survival rate was measured
by MTT assay. (C) K7, K12, K7M3, U2OS cells were treated with shikonin (3 μΜ) while 143B cells were treated with shikonin (6 μΜ) in the absence
or presence of Nec-1 (50 μΜ) for 8 hours. Nec-1 was pretreated for 2 hours before shikonin. All osteosarcoma cells had no significant changes in
G0/G1, G2/M and S phases. Data are representative of 3 independent experiments.
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To explore the mechanism of how shikonin kill osteo-
sarcoma, we added apoptosis inhibitor and necroptosis
inhibitor prior to shikonin treatment. After 8-hour incu-
bation of shikonin, the survival rate of K7, K12, K7M3,
U2OS and 143B cells was reduced to 40.03 ± 2.6, 39.86 ±
3.6, 49.73 ± 3.5, 51.08 ± 4.1, 55.21 ± 5% respectively, all
differently from that of control group (p < 0.01). After
pretreated with Nec-1 before adding shikonin, the corre-
sponding survival rate was increased to 90.25 ± 1.7,Figure 2 The induction of necroptosis in osteosarcoma cells by shiko
while 143B cells were treated with shikonin (6 μΜ) in the absence or prese
Z-VAD-FMK were pretreated for 2 hours before shikonin. The cell survival ra
sents p < 0.01. (B) K7 cells were treated with shikonin (3 μΜ) in the absenc
2 hours before shikonin. After treatment of shikonin, PI + cells increased sig
induced by shikonin decreased significantly. Data are representative of 3 in84.58 ± 4.6, 87.98 ± 2.5, 89.38 ± 1.5% in K7, K12, K7M3
and U2OS cells respectively (p < 0.01). However, the
similar increase of survival rate was not obvious for
143B cells (Figure 2A). Cell death caused by shikonin
could not be rescued by Z-VAD-FMK in 143B cells. The
death caused by shikonin in K7 cells was detected by
flow cytometry showed in Figure 2B. K7 cells was incu-
bated with shikonin (3 μΜ) for 8 hours in the absence
or presence of Nec-1 (50 μΜ), which was pretreated for
2 hours before shikonin. The percentage of PI positivenin. (A) K7, K12, K7M3, U2OS cells were treated with shikonin (3 μΜ)
nce of Nec-1 (50 μΜ) or Z-VAD-FMK (20 μΜ) for 8 hours. Nec-1 and
te was determined by MTT assay as described in Methods. ** repre-
e or presence of Nec-1 (50 μΜ) for 8 hours. Nec-1 was pretreated for
nificantly. When added with Nec-1 together with shikonin, the PI + cells
dependent experiments.
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0.001) when treated with shikonin (3 μΜ) which were
decreased to 7.03 ± 1.00% (p < 0.001) in the presence of
Nec-1 (50 μΜ) (Figure 2B). All these findings evidently
showed that shikonin is a potent necroptosis inducer in
osteosarcoma.
Shikonin induced necroptosis via upregulating RIP1 and
RIP3
RIP1 and RIP3 were regarded as crucial modulator of
necroptosis. As showed in Figure 3, the protein levels of
RIP1 and RIP3 were significantly increased in K7 and
U2OS cells after shikonin treatment for 8 hours in a
concentration dependent manner. However, caspase-3,
caspase-6 and PARP, indicators for apoptosis, were
hardly activated after being treated with shikonin for
8 hours in neither K7 nor U2OS cells. Interestingly, the
expression of RIP1 and RIP3 had no obvious change and
caspase-3, caspase-6 and PARP were not activated in
143B cells after shikonin treatment. These data indicated
that the main mechanism for shikonin in causing cell
death in osteosarcoma is to induce RIP1 and RIP3
dependent necroptosis, independent of apoptosis.
Shikonin had anti-tumor effect on primary and metastatic
osteosarcoma by inducing necroptosis
To evaluate the anti-tumor effect of shikonin in vivo, an
orthotopic osteosarcoma model was established byFigure 3 The induction of necroptosis by shikonin via upregulating R
treated with different concentrations of shikonin for 8 hours. The expressio
Western blot. The expression of the necroptosis related proteins, RIP1 and
caspase-6 and PARP were not activated in K7 and U2OS cells after being tr
changes and caspase-3, caspase-6 and PARP were not activated in 143B ce
3 independent experiments.intratibial injection of K7 cells. The mice (n = 10) were
injected with shikonin (2.0 mg/kg) while control group
(n = 10) were injected with 5% DMSO intraperitoneally
every other day for seven times in all. The general condi-
tion of mice, e.g. alertness and physical activity, was ob-
served to be normal during the whole experiment in
both groups. The mice were euthanized two days after
the last treatment. The results showed that the tumor
size in shikonin treated group was smaller compared
with control group (Figure 4A) and the weight of poster-
ior limb with tumors in shikonin treated group (0.65 ±
0.09 g) was lighter compared with control group (1.11 ±
0.39 g) significantly (p < 0.01), which both reflected the
inhibition of tumor growth with shikonin. The HE stain
of primary tumors showed that the degree of tumor ne-
crosis in shikonin group was higher compared with con-
trol group (Figure 4A). The protein levels of RIP1 and
RIP3 in primary tumor tissues gained from the mice
were significantly increased compared by shikonin treat-
ment (Figure 4C).
Since osteosarcoma mainly metastasizes to the lung,
mouse lungs were also harvested for examination. The
number of lung metastasis was significantly reduced
with shikonin treatment compared with control group
(Figure 4B) and the weight of lung in shikonin group
(0.31 ± 0.08 g) was lighter compared with control group
(0.68 ± 0.17 g) significantly (p < 0.001). The HE stain of
lung metastasis also showed that the degree of tumorIP1 and RIP3 in K7 and U2OS cells. K7, U2OS and 143B cells were
n of RIP1, RIP3, caspase-3, caspase-6 and PARP was detected by
RIP3, was increased while apoptosis related proteins, caspase-3,
eated with shikonin. The expression of RIP1 and RIP3 had no obvious
lls after being treated with shikonin. Data are representative of
Figure 4 The anti-tumor effect of shikonin on primary and metastatic osteosarcoma by inducing necroptosis in vivo. (A) Macroscopic
appearance of tibial primary osteosarcoma tumors in Balb/c mice after treatment with shikonin or 5% DMSO. The tumor size in shikonin group
was smaller than that in control group. The HE stain of primary tumors showed that the degree of tumor necrosis in shikonin group was higher
than that in control group. (B) Macroscopic appearance of lung got from tibial primary models. The lung metastaseis in shikonin group were less
than that in control group. The HE stain of lung matastasis also showed that the degree of lung matastatic tumur necrosis in shikonin group was
higher than that in control group. (C) The posterior limbs with primary tumor in shikonin group were lighter than that in control group (p < 0.01)
while the lung in shikonin group was lighter than that in control group (p < 0.001). (D) The expressional level of RIP1 and RIP3 increased in
shikonin group in primary tumor tissues compared with that in control group detected by Western blot. Data in D are representative of
3 independent experiments.
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control group (Figure 4B).
Shikonin prolonged the survival of metastatic disease
In order to test the effect of shikonin on metastatic
osteosarcoma, the mice lung metastasis models were
established by i.v injection of K7 cells. The mice in ex-
perimental group (n = 10) were injected with shikonin
(2.0 mg/kg) while control group (n = 10) were injectedwith 5% DMSO intraperitoneally every other day. Ex-
periment was ended 118 days later when 3 mice in
experiment group were alive, verse all mice died in con-
trol group. The survival time in experimental group was
significantly prolonged compared with control group
(p < 0.001) (Figure 5). These data suggested that shiko-
nin is effective against metastatic lesions in the lung, and
possibly could be developed into salvage treatment for
late stage osteosarcoma patients.
Figure 5 Survival of mice treated with DMSO and shikonin
respectively. The lung metastatic models were constructed by
osteosarcoma K7 cells in 4-week-old female Balb/c mice. The experi-
mental group (n = 10) was injected with shikonin (2.0 mg/kg, diluted
with 5% DMSO) while control group (n = 10) was injeced with 5%
DMSO intraperitoneally every other day. The survival time in shikonin
group was longer than that in control group significantly (p < 0.001).
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In this study, we used different cell lines to test the effi-
cacy of shikonin on osteosarcoma. We demonstrated
that shikonin had prompt anti-tumor effect on osteosar-
coma cells, which had no impact on cell cycle. This indi-
cated that shikonin kills osteosarcoma cells directly
rather than inhibiting proliferation. The majority of K7,
K12, K7M3 and U2OS cell death induced by shikonin
could be rescued by Nec-1, a specific inhibitor of
necroptosis, while Z-VAD-FMK, a general inhibitor of
apoptosis, had no obvious protective effect. As a potent
necroptosis inhibitor, Nec-1 was previously believed not
to inhibit apoptosis [7,14,21]. Thus the death of K7, K12,
K7M3 and U2OS cells induced by shikonin could be
considered as necroptosis. The degree of necrosis and
apoptosis were further detected by flow cytometry with
Annexin V and PI double staining. The results showed
that necrotic cells were almost totally prohibited by pre-
treatment with Nec-1 before exposure of shikonin in K7
cells. Additionally, K7 cells at late apoptotic stage were
also attenuated by Nec-1, indicating that part of those
cells might be necrotic cells. This result is similar to pre-
vious data [21]. Therefore, shikonin could kill osteosar-
coma cells quickly by inducing necroptosis at least in
some osteosarcoma cell lines.
RIP1 and RIP3 are regarded as crucial modulators of
necroptosis [8-10]. In our study, we found the protein
levels of RIP1 and RIP3 were significantly increased after
treatment with shikonin in a concentration dependent
manner in some osteosarcoma cell lines including K7
and U2OS. These results indicated that shikonin in-
duced cell death in some osteosarcoma cell lines includ-
ing K7 and U2OS via RIP1 and RIP3 dependent
necroptosis pathway. Moreover, other reports have also
shown that necroptosis could be induced via modulatingRIP1 and RIP3 [16,22-24]. Also, there were results differ-
ent from ours. Moujalled, D. M. et al. demonstrated that
TNF can activate RIP3 and cause necroptosis in the ab-
sence of RIP1 [25]. From the experiments in vivo, we
also found that the protein levels of RIP1 and RIP3 in
primary tumor tissues were increased in shikonin group
compared with control group. It can be inferred that shi-
konin had anti-tumor effect in vivo probably by inducing
necroptosis, just as the mechanism proved by the previ-
ous mentioned cell studies.
Interestingly, we found that in osteosarcoma 143B
cells, which were previously detected less sensitive to
shikonin compared with K7 and U2OS cells, cell death
induced by shikonin could neither be reduced by Nec-1
nor by Z-VAD-FMK. We also found that RIP1 and RIP3
had no obvious change while caspase-3, caspase-6 and
PARP were not activated after being treated with shiko-
nin. Different from our results, Chang, et al. found that
shikonin induces apoptosis through reactive oxygen spe-
cies/extracellular signal-regulated kinase pathway and
PARP was activated in 143B cells after being treated with
shikonin for 24 hours [26]. It may be because the treat-
ment time was different and need further study. As we
know, the 143B cell line is a Ki-ras transformed TE85
[27,28] and not sensitive to shikonin. Maybe Ki-ras is a
barrier to necroptosis. Interestingly, we also found the
cell death of SaoS2 cells induced by shikonin could not
be rescued by Nec-1(data not shown). U2OS is a p53-
positive cell line while SaoS2 is a p53-null cell line [29].
We found the protein level of p53 was increased after
treated with shikonin for 8 hours(data not shown).
Maybe p53 is a regulator of necroptosis. Above-
mentioned hypothesis is what our recent works focus on
and needs further study.
The drug-resistance of cancer is associated with apop-
totic pathway tightly, including overexpression of anti-
apoptotic proteins, mutations of pro-apoptotic proteins
and the loss of caspase [30-32]. In the clinic single-agent
activity of methotrexate, cisplatin, doxorubicin and ifosfa-
mide is approximately 40%, 30%, 40% and 30% respect-
ively [33]. Combination chemotherapy yields slightly
better results, but still approximately 40% of patients are
not sensitive. The lung metastatic osteosarcoma also ex-
hibits resistance to conventional chemotherapy. The 5-
year survival rate for patients of osteosarcoma with metas-
tasis is 20%, much lower than the corresponding survival
rate for patients with localized disease (approximately
60%), and most death associated with osteosarcoma is the
result of metastatic diseases. The specific mechanism of
drug resistance of osteosarcoma might be associated with
the activation of the Src and NF-κB pathway and the over-
expression of anti-apoptosis genes [34-36]. Based on the
results of this study, shikonin has strong anti-tumor effect
on both primary and lung metastatic osteosarcoma by
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dependent of apoptosis, all the barriers set up in cancer
cells to avoid apoptosis are no longer problems for
necroptosis.
Conclusions
Based on both in vivo and in vitro experiments, this
study proved that shikonin had prompt but profound
anti-tumor effect on both primary and metastatic osteo-
sarcoma. The main mechanism of this effect might be
inducing RIP1 and RIP3 dependent necroptosis. In order
to develop its clinical use, in the future more studies are
still required to evaluate the proper concentration and
safety of shikonin, and shikonin related drug interactions
in the treatment of osteosarcoma.
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